X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1183) 1183
Publication (75) 75
Book Review (8) 8
Book Chapter (4) 4
Book / eBook (3) 3
Conference Proceeding (3) 3
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1137) 1137
female (642) 642
male (630) 630
middle aged (530) 530
hematology (478) 478
oncology (472) 472
aged (464) 464
myelodysplastic syndromes - chemically induced (460) 460
adult (432) 432
index medicus (409) 409
myelodysplastic syndrome (326) 326
myelodysplastic syndromes (293) 293
acute myeloid-leukemia (264) 264
myelodysplastic syndromes - drug therapy (251) 251
myelodysplastic syndromes - genetics (217) 217
antineoplastic agents - adverse effects (207) 207
leukemia (202) 202
cancer (200) 200
aged, 80 and over (185) 185
antineoplastic combined chemotherapy protocols - adverse effects (184) 184
leukemia, myeloid, acute - chemically induced (183) 183
chemotherapy (168) 168
adolescent (153) 153
treatment outcome (153) 153
acute disease (151) 151
neoplasms, second primary - chemically induced (147) 147
risk factors (144) 144
antineoplastic combined chemotherapy protocols - therapeutic use (143) 143
myelodysplastic syndromes - pathology (132) 132
therapy (131) 131
risk (118) 118
child (113) 113
retrospective studies (106) 106
acute myelogenous leukemia (104) 104
acute nonlymphocytic leukemia (100) 100
animals (100) 100
myelodysplastic syndromes - complications (98) 98
antineoplastic agents - therapeutic use (97) 97
chromosome aberrations (95) 95
leukemia - chemically induced (91) 91
myelodysplastic syndromes - therapy (91) 91
neutropenia - chemically induced (90) 90
leukemia, myeloid - chemically induced (88) 88
prognosis (86) 86
leukemia, myeloid, acute - genetics (85) 85
myelodysplastic syndromes - epidemiology (82) 82
leukemia, myeloid, acute - drug therapy (79) 79
follow-up studies (77) 77
care and treatment (76) 76
child, preschool (75) 75
medicine & public health (75) 75
remission induction (75) 75
azacitidine - adverse effects (74) 74
transplantation (74) 74
acute lymphoblastic-leukemia (73) 73
karyotyping (73) 73
acute myeloid leukemia (70) 70
hematology, oncology and palliative medicine (70) 70
neoplasms - drug therapy (68) 68
combined modality therapy (67) 67
research (67) 67
incidence (65) 65
myelodysplastic syndromes - diagnosis (64) 64
pharmacology & pharmacy (64) 64
colony-stimulating factor (63) 63
antimetabolites, antineoplastic - adverse effects (62) 62
drug administration schedule (62) 62
dose-response relationship, drug (61) 61
myelodysplastic syndromes - etiology (61) 61
leukemia, myeloid - genetics (60) 60
neoplasms, second primary - genetics (60) 60
azacitidine - therapeutic use (59) 59
time factors (58) 58
health aspects (57) 57
survival analysis (57) 57
young adult (57) 57
fatal outcome (55) 55
infant (54) 54
myelodysplastic syndromes - mortality (54) 54
acute promyelocytic leukemia (53) 53
cyclophosphamide - adverse effects (53) 53
cytarabine - administration & dosage (53) 53
bone marrow - pathology (52) 52
cyclophosphamide (52) 52
mutation (51) 51
stem-cell transplantation (50) 50
translocation, genetic (50) 50
analysis (49) 49
antineoplastic agents, alkylating - adverse effects (49) 49
azacitidine (49) 49
immunosuppressive agents - adverse effects (49) 49
thrombocytopenia - chemically induced (49) 49
genetics & heredity (48) 48
survival rate (48) 48
breast neoplasms - drug therapy (47) 47
dna methylation (47) 47
chromosome deletion (46) 46
medicine, general & internal (45) 45
clinical trials as topic (44) 44
bone marrow transplantation (43) 43
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1124) 1124
Japanese (21) 21
German (12) 12
Chinese (9) 9
French (5) 5
Polish (4) 4
Spanish (4) 4
Norwegian (3) 3
Italian (2) 2
Dutch (1) 1
Hungarian (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2007, Volume 25, Issue 5, pp. 493 - 500
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 112 - 121
Summary Background Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | BREAST-CANCER | COLON-CANCER | VARIANTS | ONCOLOGY | FORMAT | SEQUENCE | MUTATIONS | LEUKEMIA | OUTCOMES | MYELODYSPLASTIC SYNDROMES | Clone Cells - drug effects | Prognosis | Follow-Up Studies | Humans | Leukemia, Myeloid, Acute - epidemiology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Case-Control Studies | Incidence | Neoplasms, Second Primary - chemically induced | Myelodysplastic Syndromes - chemically induced | Aged, 80 and over | Female | Neoplasms, Second Primary - genetics | High-Throughput Nucleotide Sequencing - methods | Leukemia, Myeloid, Acute - chemically induced | Florida - epidemiology | Risk Factors | Hematopoiesis - genetics | Survival Rate | Mutation - genetics | Myelodysplastic Syndromes - epidemiology | Clone Cells - metabolism | Neoplasms - drug therapy | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - epidemiology | Myelodysplastic Syndromes - diagnosis | Clone Cells - pathology | Leukemia, Myeloid, Acute - diagnosis | Aged | Biomarkers, Tumor - genetics | Myelodysplastic Syndromes - genetics | Neoplasm Staging | Neoplasms - pathology | Leukemia, Myeloid, Acute - genetics | Care and treatment | Chemotherapy | Oncology, Experimental | Mortality | Aged patients | Research | Epidemiology | Cancer | Development and progression
Journal Article
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 06/2015, Volume 56, Issue 6, pp. 1643 - 1650
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2012, Volume 104, Issue 22, pp. 1724 - 1737
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 13, pp. 2124 - 2130
Purpose Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival ( OS) in patients with... 
LIVER METASTASES | STREPTOZOCIN | CHEMOEMBOLIZATION | SOUTHWEST-ONCOLOGY-GROUP | ONCOLOGY | CARCINOID-TUMORS | RADIONUCLIDE THERAPY | ENDOCRINE TUMORS | PHASE-II | METASTATIC NEUROENDOCRINE TUMORS | EPIDEMIOLOGY | Gastrointestinal Neoplasms - mortality | Humans | Middle Aged | Male | Gastrointestinal Neoplasms - pathology | Time Factors | Myelodysplastic Syndromes - chemically induced | Neuroendocrine Tumors - diagnostic imaging | Aged, 80 and over | Organometallic Compounds - therapeutic use | Adult | Female | Pancreatic Neoplasms - mortality | Neuroendocrine Tumors - pathology | Severity of Illness Index | Hematologic Diseases - chemically induced | Octreotide - analogs & derivatives | Risk Assessment | Organometallic Compounds - adverse effects | Pancreatic Neoplasms - pathology | Proportional Hazards Models | Carcinoid Tumor - diagnostic imaging | Octreotide - adverse effects | Logistic Models | Treatment Outcome | Octreotide - therapeutic use | Carcinoid Tumor - pathology | Disease-Free Survival | Gastrointestinal Neoplasms - diagnostic imaging | Neuroendocrine Tumors - mortality | Radionuclide Imaging | Aged | Chemical and Drug Induced Liver Injury | Radiopharmaceuticals - adverse effects | Carcinoid Tumor - mortality | Pancreatic Neoplasms - diagnostic imaging | Radiopharmaceuticals - therapeutic use | Index Medicus
Journal Article
Oncology (Williston Park, N.Y.), ISSN 0890-9091, 07/2018, Volume 32, Issue 7, pp. 339 - 343
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 16, pp. 3673 - 3678
We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenstrom macroglobulinemia (WM). WM patients with... 
MULTIPLE-MYELOMA | PROGNOSTIC FACTORS | MANTLE-CELL LYMPHOMA | TREATMENT RECOMMENDATIONS | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHASE-II | FOLLICULAR LYMPHOMA | LOW-GRADE | HEMATOLOGY | 3RD INTERNATIONAL WORKSHOP | COOPERATIVE-ONCOLOGY-GROUP | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasms, Second Primary - mortality | Waldenstrom Macroglobulinemia - diet therapy | Pneumonia - mortality | Time Factors | Neoplasms, Second Primary - chemically induced | Pneumonia - chemically induced | Myelodysplastic Syndromes - chemically induced | Neutropenia - mortality | Female | Waldenstrom Macroglobulinemia - mortality | Leukemia, Myeloid, Acute - chemically induced | Neutropenia - chemically induced | Antibodies, Monoclonal, Murine-Derived | Vidarabine - adverse effects | Rituximab | Survival Rate | Thrombocytopenia - chemically induced | Vidarabine - analogs & derivatives | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Myelodysplastic Syndromes - mortality | Thrombocytopenia - mortality | Aged | Vidarabine - administration & dosage | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 02/2011, Volume 162, Issue 4, pp. 792 - 805
Therapy‐related myeloid neoplasms (t‐MNs) are serious long‐term consequences of cytotoxic treatments for an antecedent disorder. t‐MNs are observed after... 
alkylating agents | stem cell transplantation | antimetabolites | therapy‐related myeloid neoplasms | therapy‐related myelodysplastic syndrome | therapy‐related acute myeloid leukaemia | granulocyte‐colony stimulating factor | genetic susceptibility | topoisomerase‐II‐inhibitors | ionizing radiation | topoisomerase-II-inhibitors | granulocyte-colony stimulating factor | therapy-related acute myeloid leukaemia | therapy-related myeloid neoplasms | therapy-related myelodysplastic syndrome | ACUTE MYELOMONOCYTIC LEUKEMIA | COLONY-STIMULATING FACTOR | DNA-TOPOISOMERASE-II | CONVENTIONAL CARE REGIMENS | LI-FRAUMENI-SYNDROME | ACUTE LYMPHOBLASTIC-LEUKEMIA | CAUSE NOONAN-SYNDROME | PHARMACOLOGY & PHARMACY | STEM-CELL TRANSPLANTATION | ACUTE PROMYELOCYTIC LEUKEMIA | GENOME-WIDE ASSOCIATION | Genetic Predisposition to Disease | Myelodysplastic Syndromes - physiopathology | Prognosis | Humans | Hematopoietic Stem Cell Transplantation | Radiotherapy - adverse effects | Myelodysplastic Syndromes - therapy | Animals | Antineoplastic Agents - adverse effects | Neoplasms, Second Primary - chemically induced | Neoplasms, Second Primary - therapy | Myelodysplastic Syndromes - chemically induced | Myelodysplastic Syndromes - genetics | Neoplasms, Second Primary - physiopathology | Neoplasms, Second Primary - genetics | Leukemia, Myeloid, Acute - chemically induced | Leukemia, Myeloid, Acute - physiopathology | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Bone marrow | Cytotoxicity | Transplants & implants | Mortality | Tumors | Reviews
Journal Article